The content on this site is intended for healthcare professionals only
Dr Giulia Pasello speaks to ecancer about the phase II CHIMERA trial.
The trial evaluates neoadjuvant pembrolizumab plus platinum-based chemotherapy followed by pleurectomy and decortication in patients with resectable pleural mesothelioma.
The approach achieved a complete macroscopic resection in 95.1% of patients, with a pathological complete response rate of 10.3% and major pathological response in 23.1%.
Dr Pasello says that although the prespecified threshold for clinical activity was not met, the combination was feasible and showed encouraging pathological responses, with quality of life largely maintained during neoadjuvant treatment.
Cemiplimab shows strong survival benefit in KRAS G12C positive advanced NSCLC
Amivantamab plus chemotherapy extends overall survival in EGFR exon 20 insertion NSCLC
JS207 plus chemotherapy enables surgery and deep pathological responses in unresectable NSCLC
Tarlatamab improves brain metastases control and survival compared to chemo in SCLC
Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC
Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in perioperative lung cancer management?
Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC
MK-1084 plus pembrolizumab achieves high response rates in KRAS G12C mutated non-small cell lung cancer
Durvalumab improves survival and delays progression in limited-stage small cell lung cancer
